Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Adicet Bio (DE:1IJA)
FRANKFURT:1IJA
Adicet Bio (1IJA) Stock Price & Analysis
0 Followers
1IJA Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€0.92 - €6.80
Previous Close€1.28
Volume0.00
Average Volume (3M)1.07K
Market Cap
€110.61M
Enterprise Value-€18.92M
Total Cash (Recent Filing)$159.71M
Total Debt (Recent Filing)$20.92M
Price to Earnings (P/E)N/A
Beta0.37
Next Earnings
May 08, 2024EPS Estimate
-€0.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding82,153,984
10 Day Avg. Volume0
30 Day Avg. Volume1,067
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)0.70
Price to Sales (P/S)147.05
Price to Cash Flow (P/CF)-1.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-26.49
Enterprise Value/Gross Profit-26.49
Enterprise Value/Ebitda0.14
Forecast
1Y Price Target
€8.57Price Target Upside570.45% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Adicet Bio News
PremiumCompany Announcements
Adicet Bio Showcases Promising ADI-270 Cancer Therapy Data
PremiumPre-Earnings
Is ACET a Buy, Before Earnings?
Bulls Say, Bears Say
Bulls Say
Clinical Development ProgressAdicet's ADI-001 shows strong promise in clinical development, with an 80% complete response rate in MCL patients, suggesting potential efficacy of the treatment.
Financial StabilityAdicet's solid cash position is expected to fund operations well into the future, underpinning the company's financial stability.
Regulatory MilestonesThe FDA has approved Adicet's IND for lupus nephritis, allowing the company to proceed with clinical trials, demonstrating regulatory progress.
Bears Say
Analyst RatingAnalyst maintains a Market Perform rating, remaining on the sidelines until key data updates are released regarding the company's clinical developments.
Financial PerformanceAdicet reported 2023 EPS of $(3.31), indicating a loss per share for the year.
Future ExpectationsAnalysts maintain a Market Perform rating on Adicet, awaiting key data updates expected in the future.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
4.80% Other Institutional Investors
95.20% Public Companies and
Individual Investors
1IJA FAQ
What was Adicet Bio’s price range in the past 12 months?
Adicet Bio lowest stock price was €0.92 and its highest was €6.80 in the past 12 months.
What is Adicet Bio’s market cap?
Currently, no data Available
When is Adicet Bio’s upcoming earnings report date?
Adicet Bio’s upcoming earnings report date is May 08, 2024 which is in 3 days.
How were Adicet Bio’s earnings last quarter?
Adicet Bio released its earnings results on Mar 19, 2024. The company reported -€0.644 earnings per share for the quarter, beating the consensus estimate of -€0.65 by €0.007.
Is Adicet Bio overvalued?
According to Wall Street analysts Adicet Bio’s price is currently Undervalued.
Does Adicet Bio pay dividends?
Adicet Bio does not currently pay dividends.
What is Adicet Bio’s EPS estimate?
Adicet Bio’s EPS estimate is -€0.41.
How many shares outstanding does Adicet Bio have?
Currently, no data Available
What happened to Adicet Bio’s price movement after its last earnings report?
Adicet Bio reported an EPS of -€0.644 in its last earnings report, beating expectations of -€0.65. Following the earnings report the stock price went up 1.527%.
Which hedge fund is a major shareholder of Adicet Bio?
Among the largest hedge funds holding Adicet Bio’s share is Wexford Capital LP. It holds Adicet Bio’s shares valued at 28K.
---
Adicet Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€8.57 (570.45% Upside)
€8.57 (570.45% Upside)
Blogger Sentiment
Bullish
DE:1IJA Sentiment 100%
Sector Average 70%
Sector Average 70%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-77.12%
12-Months-Change
Fundamentals
Return on Equity
-61.69%
Trailing 12-Months
Asset Growth
-37.31%
Trailing 12-Months
Company Description
Adicet Bio
resTORbio, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the development and commercialization of medicines for aging-related diseases and conditions. It offers an immunotherapy under the TORC1 program. The company was founded by Chen Schor and Joan Mannick on July 5, 2016 and is headquartered in Boston, MA.
---
1IJA Stock 12 Months Forecast
Average Price Target
€8.57
▲(570.45% Upside)
Technical Analysis
Best Analysts Covering 1IJA
1 Year
1 Year Success Rate
5/15 ratings generated profit
1 Year Average Return
-3.30%
reiterated a buy rating 2 months ago
Copying Justin Zelin's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -3.30% per trade.
---